BR112023023061A2 - Terapia de células t com receptor de antígeno quimérico específico de cd19 - Google Patents

Terapia de células t com receptor de antígeno quimérico específico de cd19

Info

Publication number
BR112023023061A2
BR112023023061A2 BR112023023061A BR112023023061A BR112023023061A2 BR 112023023061 A2 BR112023023061 A2 BR 112023023061A2 BR 112023023061 A BR112023023061 A BR 112023023061A BR 112023023061 A BR112023023061 A BR 112023023061A BR 112023023061 A2 BR112023023061 A2 BR 112023023061A2
Authority
BR
Brazil
Prior art keywords
antigen receptor
chimeric antigen
cell therapy
specific chimeric
specific
Prior art date
Application number
BR112023023061A
Other languages
English (en)
Portuguese (pt)
Inventor
Boronat Barado Ana
Esteve Reyner Jordi
Yagüe Ribes Jordi
Delgado González Julio
Juan Otero Manel
Pascal Capdevila Mariona
Castellà Castellà María
Urbano Ispizua Álvaro
Original Assignee
Fundacio De Recerca Clinic Barcelona Inst D¿Investigacions Biomediques August Pi I Sunyer
Hospital Clinic Barcelona
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio De Recerca Clinic Barcelona Inst D¿Investigacions Biomediques August Pi I Sunyer, Hospital Clinic Barcelona, Univ Barcelona filed Critical Fundacio De Recerca Clinic Barcelona Inst D¿Investigacions Biomediques August Pi I Sunyer
Publication of BR112023023061A2 publication Critical patent/BR112023023061A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023023061A 2021-05-06 2022-05-06 Terapia de células t com receptor de antígeno quimérico específico de cd19 BR112023023061A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2021/070316 WO2022234158A1 (es) 2021-05-06 2021-05-06 Terapia de células t con receptor de antígeno quimérico específico de cd19
PCT/EP2022/062374 WO2022234134A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Publications (1)

Publication Number Publication Date
BR112023023061A2 true BR112023023061A2 (pt) 2024-01-30

Family

ID=76355528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023061A BR112023023061A2 (pt) 2021-05-06 2022-05-06 Terapia de células t com receptor de antígeno quimérico específico de cd19

Country Status (11)

Country Link
US (1) US20240398945A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334357A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024519529A (cg-RX-API-DMAC10.html)
AU (1) AU2022270952A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023023061A2 (cg-RX-API-DMAC10.html)
CA (1) CA3219214A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003299A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023016940A2 (cg-RX-API-DMAC10.html)
JO (1) JOP20230269A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013088A (cg-RX-API-DMAC10.html)
WO (2) WO2022234158A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025040765A (ja) * 2023-09-12 2025-03-25 国立大学法人三重大学 Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、細胞傷害活性を向上させる方法、並びにｃａｒを含む免疫細胞の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
SI2997141T1 (sl) * 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP7089806B2 (ja) * 2017-12-06 2022-06-23 アブクロン・インコーポレイテッド 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
US12331114B2 (en) * 2018-02-13 2025-06-17 Indian Institute Of Technology Bombay Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도

Also Published As

Publication number Publication date
CA3219214A1 (en) 2022-11-10
MX2023013088A (es) 2024-01-24
CL2023003299A1 (es) 2024-07-05
EP4334357A1 (en) 2024-03-13
JOP20230269A1 (ar) 2023-10-26
US20240398945A1 (en) 2024-12-05
WO2022234134A1 (en) 2022-11-10
AU2022270952A1 (en) 2023-11-16
JP2024519529A (ja) 2024-05-15
WO2022234158A1 (es) 2022-11-10
CO2023016940A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
CL2020003026A1 (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CO2022014820A2 (es) Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2023014921A (es) Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana.
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
MY204673A (en) Humanized anti-sirp antibodies
MX2025003354A (es) Anticuerpos que se unen a 5t4
MX2009004106A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3.
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
CL2024002748A1 (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinación en el tratamiento del cáncer.
CL2023003893A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcohólica.
BR112022017162A2 (pt) Terapia anti-cd19 em combinação com lenalidomida para o tratamento de leucemia ou linfoma
BR112015008143A2 (pt) complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições
CL2022002520A1 (es) Anticuerpos anti-sea de muc1
CO2024003578A2 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
CL2023000916A1 (es) Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3.
MX2021007283A (es) Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
SE1750203A1 (en) Novel peptides and their use in diagnosis